Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Equillium, Inc.EQ · Entity 6560 | Sr. Vice President and COO | June 05, 2026 | June 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Equillium, Inc.
Report date June 05, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 62,586 |
Ending reported balance
After 2026-06-05 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-06-05 · Exercise / conversion · Acquired 14,584 · Balance 77,170 Row 2 · 2026-06-05 · Sale · Disposed 14,584 · Balance 62,586 F1: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 27, 2025. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.91 to $2.95, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.79 · Expires 2033-01-02 | Direct | 25,521 |
Reported balance
After 2026-06-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-05 · Exercise / conversion · Disposed 14,584 · Balance 25,521 F3: Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 27, 2025.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.91 to $2.95, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3: Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 14, 2025 Filed Feb 20, 2025 00:44 UTC | Equillium, Inc. EQ · Entity 6560 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 100,000 | Not disclosed Strike: $5.03 | Not disclosed |
DisclosureSEC source: 0001415889-25-004763 · form4-02202025_120255.xml · derivative · entry 8 Zedelmayer Christine · CIK 0001797818 · Sr. Vice President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2031-01-03 F2 · price: On August 7, 2023, the Board of Directors of the Company approved the repricing of certain options based on the closing price of the Company's common stock on August 14, 2023. The repricing of these options was subject to a holding period that lapsed on February 14, 2025. The repricing resulted in the impacted options having a lower exercise price of $0.785 per share, which is the closing price of the Company's common stock on the Nasdaq Capital Market on August 14, 2023. All of the other terms of the options remained unchanged. F1 · derivative.exercise_date: Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years. Read SEC document |
| February 14, 2025 Filed Feb 20, 2025 00:44 UTC | Equillium, Inc. EQ · Entity 6560 | GrantEmployee Stock Option (right to buy) · Derivative | 100,000 | Not disclosed Strike: $0.79 | Not disclosed |
DisclosureSEC source: 0001415889-25-004763 · form4-02202025_120255.xml · derivative · entry 7 Zedelmayer Christine · CIK 0001797818 · Sr. Vice President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2031-01-03 F2 · price: On August 7, 2023, the Board of Directors of the Company approved the repricing of certain options based on the closing price of the Company's common stock on August 14, 2023. The repricing of these options was subject to a holding period that lapsed on February 14, 2025. The repricing resulted in the impacted options having a lower exercise price of $0.785 per share, which is the closing price of the Company's common stock on the Nasdaq Capital Market on August 14, 2023. All of the other terms of the options remained unchanged. F1 · derivative.exercise_date: Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years. Read SEC document |
| February 14, 2025 Filed Feb 20, 2025 00:44 UTC | Equillium, Inc. EQ · Entity 6560 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 75,000 | Not disclosed Strike: $2.45 | Not disclosed |
DisclosureSEC source: 0001415889-25-004763 · form4-02202025_120255.xml · derivative · entry 6 Zedelmayer Christine · CIK 0001797818 · Sr. Vice President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 75,000 shares Expires 2029-12-09 F2 · price: On August 7, 2023, the Board of Directors of the Company approved the repricing of certain options based on the closing price of the Company's common stock on August 14, 2023. The repricing of these options was subject to a holding period that lapsed on February 14, 2025. The repricing resulted in the impacted options having a lower exercise price of $0.785 per share, which is the closing price of the Company's common stock on the Nasdaq Capital Market on August 14, 2023. All of the other terms of the options remained unchanged. F1 · derivative.exercise_date: Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years. Read SEC document |
| February 14, 2025 Filed Feb 20, 2025 00:44 UTC | Equillium, Inc. EQ · Entity 6560 | GrantEmployee Stock Option (right to buy) · Derivative | 75,000 | Not disclosed Strike: $0.79 | Not disclosed |
DisclosureSEC source: 0001415889-25-004763 · form4-02202025_120255.xml · derivative · entry 5 Zedelmayer Christine · CIK 0001797818 · Sr. Vice President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2029-12-09 F2 · price: On August 7, 2023, the Board of Directors of the Company approved the repricing of certain options based on the closing price of the Company's common stock on August 14, 2023. The repricing of these options was subject to a holding period that lapsed on February 14, 2025. The repricing resulted in the impacted options having a lower exercise price of $0.785 per share, which is the closing price of the Company's common stock on the Nasdaq Capital Market on August 14, 2023. All of the other terms of the options remained unchanged. F1 · derivative.exercise_date: Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years. Read SEC document |
| February 14, 2025 Filed Feb 20, 2025 00:44 UTC | Equillium, Inc. EQ · Entity 6560 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 41,666 | Not disclosed Strike: $2.45 | Not disclosed |
DisclosureSEC source: 0001415889-25-004763 · form4-02202025_120255.xml · derivative · entry 4 Zedelmayer Christine · CIK 0001797818 · Sr. Vice President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 41,666 shares Expires 2029-02-12 F2 · price: On August 7, 2023, the Board of Directors of the Company approved the repricing of certain options based on the closing price of the Company's common stock on August 14, 2023. The repricing of these options was subject to a holding period that lapsed on February 14, 2025. The repricing resulted in the impacted options having a lower exercise price of $0.785 per share, which is the closing price of the Company's common stock on the Nasdaq Capital Market on August 14, 2023. All of the other terms of the options remained unchanged. F1 · derivative.exercise_date: Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years. Read SEC document |
| February 14, 2025 Filed Feb 20, 2025 00:44 UTC | Equillium, Inc. EQ · Entity 6560 | GrantEmployee Stock Option (right to buy) · Derivative | 41,666 | Not disclosed Strike: $0.79 | Not disclosed |
DisclosureSEC source: 0001415889-25-004763 · form4-02202025_120255.xml · derivative · entry 3 Zedelmayer Christine · CIK 0001797818 · Sr. Vice President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,666 Underlying: Common Stock · 41,666 shares Expires 2029-02-12 F2 · price: On August 7, 2023, the Board of Directors of the Company approved the repricing of certain options based on the closing price of the Company's common stock on August 14, 2023. The repricing of these options was subject to a holding period that lapsed on February 14, 2025. The repricing resulted in the impacted options having a lower exercise price of $0.785 per share, which is the closing price of the Company's common stock on the Nasdaq Capital Market on August 14, 2023. All of the other terms of the options remained unchanged. F1 · derivative.exercise_date: Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years. Read SEC document |
| February 14, 2025 Filed Feb 20, 2025 00:44 UTC | Equillium, Inc. EQ · Entity 6560 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 35,695 | Not disclosed Strike: $2.45 | Not disclosed |
DisclosureSEC source: 0001415889-25-004763 · form4-02202025_120255.xml · derivative · entry 2 Zedelmayer Christine · CIK 0001797818 · Sr. Vice President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,695 shares Expires 2028-09-12 F2 · price: On August 7, 2023, the Board of Directors of the Company approved the repricing of certain options based on the closing price of the Company's common stock on August 14, 2023. The repricing of these options was subject to a holding period that lapsed on February 14, 2025. The repricing resulted in the impacted options having a lower exercise price of $0.785 per share, which is the closing price of the Company's common stock on the Nasdaq Capital Market on August 14, 2023. All of the other terms of the options remained unchanged. F1 · derivative.exercise_date: Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years. Read SEC document |
| February 14, 2025 Filed Feb 20, 2025 00:44 UTC | Equillium, Inc. EQ · Entity 6560 | GrantEmployee Stock Option (right to buy) · Derivative | 35,695 | Not disclosed Strike: $0.79 | Not disclosed |
DisclosureSEC source: 0001415889-25-004763 · form4-02202025_120255.xml · derivative · entry 1 Zedelmayer Christine · CIK 0001797818 · Sr. Vice President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,695 Underlying: Common Stock · 35,695 shares Expires 2028-09-12 F2 · price: On August 7, 2023, the Board of Directors of the Company approved the repricing of certain options based on the closing price of the Company's common stock on August 14, 2023. The repricing of these options was subject to a holding period that lapsed on February 14, 2025. The repricing resulted in the impacted options having a lower exercise price of $0.785 per share, which is the closing price of the Company's common stock on the Nasdaq Capital Market on August 14, 2023. All of the other terms of the options remained unchanged. F1 · derivative.exercise_date: Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 23:09 UTC | Equillium, Inc. EQ · Entity 6560 | GrantEmployee Stock Option (right to buy) · Derivative | 175,000 | $0.00 Strike: $0.77 | $0.00 |
DisclosureSEC source: 0001415889-25-000841 · form4-01062025_110148.xml · derivative · entry 1 Zedelmayer Christine · CIK 0001797818 · Sr. Vice President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2035-01-01 F1 · derivative.exercise_date: Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years. Read SEC document |
| October 28, 2024 Filed Oct 31, 2024 00:59 UTC | Equillium, Inc. EQ · Entity 6560 | SaleCommon Stock | 15,000 | $1.25 | $18,750.00 |
DisclosureSEC source: 0001415889-24-025804 · form4-10312024_121034.xml · nonDerivative · entry 1 Zedelmayer Christine · CIK 0001797818 · Sr. Vice President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 135,246 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 19, 2024. F2 · balance_after: Includes 15,000 shares acquired by the reporting person on June 10, 2024 under the Issuer's 2018 Employee Stock Purchase Plan. Read SEC document |
| January 02, 2024 Filed Jan 3, 2024 23:12 UTC | Equillium, Inc. EQ · Entity 6560 | GrantEmployee Stock Option (right to buy) · Derivative | 175,000 | $0.00 Strike: $0.73 | $0.00 |
DisclosureSEC source: 0001209191-24-000516 · doc4.xml · derivative · entry 3 Zedelmayer Christine · CIK 0001797818 · Sr. Vice President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2034-01-01 F2 · derivative.exercise_date: Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years. Read SEC document |
| December 08, 2023 Filed Jan 3, 2024 23:12 UTC | Equillium, Inc. EQ · Entity 6560 | GrantCommon Stock | 8,804 | $0.58 | $5,106.32 |
DisclosureSEC source: 0001209191-24-000516 · doc4.xml · nonDerivative · entry 2 Zedelmayer Christine · CIK 0001797818 · Sr. Vice President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 135,246 F1 · kind: These shares were acquired by the Reporting Person under the Issuer's 2018 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| June 09, 2023 Filed Jan 3, 2024 23:12 UTC | Equillium, Inc. EQ · Entity 6560 | GrantCommon Stock | 15,000 | $0.56 | $8,400.00 |
DisclosureSEC source: 0001209191-24-000516 · doc4.xml · nonDerivative · entry 1 Zedelmayer Christine · CIK 0001797818 · Sr. Vice President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 126,442 F1 · kind: These shares were acquired by the Reporting Person under the Issuer's 2018 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| January 03, 2023 Filed Jan 4, 2023 23:43 UTC | Equillium, Inc. EQ · Entity 6560 | GrantEmployee Stock Option (right to buy) · Derivative | 175,000 | $0.00 Strike: $1.06 | $0.00 |
DisclosureSEC source: 0001209191-23-001362 · doc4.xml · derivative · entry 2 Zedelmayer Christine · CIK 0001797818 · Sr. Vice President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2033-01-02 F2 · derivative.exercise_date: Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years. Read SEC document |
| June 10, 2022 Filed Jan 4, 2023 23:43 UTC | Equillium, Inc. EQ · Entity 6560 | GrantCommon Stock | 9,033 | $1.85 | $16,711.05 |
DisclosureSEC source: 0001209191-23-001362 · doc4.xml · nonDerivative · entry 1 Zedelmayer Christine · CIK 0001797818 · Sr. Vice President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,442 F1 · kind: These shares were acquired by the Reporting Person under the Issuer's 2018 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| January 19, 2022 Filed Feb 7, 2023 23:34 UTC | Equillium, Inc. EQ · Entity 6560 | GrantEmployee Stock Option (right to buy) · Derivative | 125,000 | $0.00 Strike: $3.86 | $0.00 |
DisclosureSEC source: 0001209191-23-007671 · doc4.xml · derivative · entry 1 Zedelmayer Christine · CIK 0001797818 · Sr. Vice President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2032-01-18 F1 · derivative.exercise_date: Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years. Read SEC document |
| November 16, 2021 Filed Nov 17, 2021 20:27 UTC | Equillium, Inc. EQ · Entity 6560 | Exercise / conversionEmployee Stock Option · Derivative | 15,000 | $0.00 Strike: $2.45 | $0.00 |
DisclosureSEC source: 0001209191-21-065041 · doc4.xml · derivative · entry 6 Zedelmayer Christine · CIK 0001797818 · Sr. Vice President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 15,000 shares Expires 2029-12-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · balance_after: In accordance with Instruction 4 to this Form, Column 9 reports only total beneficial ownership of the "class" of derivative security reported in Column 1. Options that have different exercise prices or expiration dates are not considered to be of the same "class." Read SEC document |
| November 16, 2021 Filed Nov 17, 2021 20:27 UTC | Equillium, Inc. EQ · Entity 6560 | Exercise / conversionEmployee Stock Option · Derivative | 8,334 | $0.00 Strike: $2.45 | $0.00 |
DisclosureSEC source: 0001209191-21-065041 · doc4.xml · derivative · entry 5 Zedelmayer Christine · CIK 0001797818 · Sr. Vice President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,666 Underlying: Common Stock · 8,334 shares Expires 2029-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · balance_after: In accordance with Instruction 4 to this Form, Column 9 reports only total beneficial ownership of the "class" of derivative security reported in Column 1. Options that have different exercise prices or expiration dates are not considered to be of the same "class." Read SEC document |
| November 16, 2021 Filed Nov 17, 2021 20:27 UTC | Equillium, Inc. EQ · Entity 6560 | SaleCommon Stock | 7,350 | $5.49 | $40,314.75 |
DisclosureSEC source: 0001209191-21-065041 · doc4.xml · nonDerivative · entry 4 Zedelmayer Christine · CIK 0001797818 · Sr. Vice President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,409 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2021. The transaction was a sell-to-cover exercise, with shares sold to cover the option exercise price and taxes. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.40 to $5.59, inclusive. The reporting person undertakes to provide to Equillium, Inc., any security holder of Equillium, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) to this Form 4. Read SEC document |
| November 16, 2021 Filed Nov 17, 2021 20:27 UTC | Equillium, Inc. EQ · Entity 6560 | Exercise / conversionCommon Stock | 15,000 | $2.45 | $36,750.00 |
DisclosureSEC source: 0001209191-21-065041 · doc4.xml · nonDerivative · entry 3 Zedelmayer Christine · CIK 0001797818 · Sr. Vice President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,759 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The stock option exercises reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 17, 2021. Read SEC document |
| November 16, 2021 Filed Nov 17, 2021 20:27 UTC | Equillium, Inc. EQ · Entity 6560 | SaleCommon Stock | 4,084 | $5.49 | $22,400.74 |
DisclosureSEC source: 0001209191-21-065041 · doc4.xml · nonDerivative · entry 2 Zedelmayer Christine · CIK 0001797818 · Sr. Vice President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,759 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2021. The transaction was a sell-to-cover exercise, with shares sold to cover the option exercise price and taxes. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.40 to $5.59, inclusive. The reporting person undertakes to provide to Equillium, Inc., any security holder of Equillium, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) to this Form 4. Read SEC document |
| November 16, 2021 Filed Nov 17, 2021 20:27 UTC | Equillium, Inc. EQ · Entity 6560 | Exercise / conversionCommon Stock | 8,334 | $2.45 | $20,418.30 |
DisclosureSEC source: 0001209191-21-065041 · doc4.xml · nonDerivative · entry 1 Zedelmayer Christine · CIK 0001797818 · Sr. Vice President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,843 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The stock option exercises reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 17, 2021. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 21:56 UTC | Equillium, Inc. EQ · Entity 6560 | GrantCommon stock, par value $0.0001 per share | 9,032 | $2.35 | $21,225.20 |
DisclosureSEC source: 0001209191-21-040316 · doc4.xml · nonDerivative · entry 1 Zedelmayer Christine · CIK 0001797818 · Sr. Vice President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,509 F1 · kind: The shares were acquired by the Reporting Person under the Issuer's 2018 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(c) and Rule 16b-3(d). Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 22:00 UTC | Equillium, Inc. EQ · Entity 6560 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $5.03 | $0.00 |
DisclosureSEC source: 0001209191-21-002167 · doc4.xml · derivative · entry 1 Zedelmayer Christine · CIK 0001797818 · Sr. Vice President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2031-01-03 F1 · derivative.exercise_date: Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years. Read SEC document |
| December 10, 2020 Filed Dec 11, 2020 22:00 UTC | Equillium, Inc. EQ · Entity 6560 | OtherCommon Stock | 1,097 | $2.35 | $2,577.95 |
DisclosureSEC source: 0001209191-20-062992 · doc4.xml · nonDerivative · entry 1 Zedelmayer Christine · CIK 0001797818 · Sr. Vice President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,477 F1 · kind: Represents shares acquired by the Reporting Person under the Issuer's 2018 Employee Stock Purchase Plan. Read SEC document |
| June 10, 2020 Filed Jun 12, 2020 20:30 UTC | Equillium, Inc. EQ · Entity 6560 | OtherCommon Stock | 9,570 | $2.41 | $23,063.70 |
DisclosureSEC source: 0001209191-20-036284 · doc4.xml · nonDerivative · entry 1 Zedelmayer Christine · CIK 0001797818 · Sr. Vice President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,380 F1 · kind: Represents shares acquired by the Reporting Person under the Issuer's 2018 Employee Stock Purchase Plan. Read SEC document |
| April 22, 2020 Filed Apr 24, 2020 21:30 UTC | Equillium, Inc. EQ · Entity 6560 | GrantStock Option (right to buy) · Derivative | 90,000 | Not disclosed Strike: $2.45 | Not disclosed |
DisclosureSEC source: 0001209191-20-025655 · doc4.xml · derivative · entry 6 Zedelmayer Christine · CIK 0001797818 · Sr. Vice President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2029-12-09 F4 · price: Effective April 22, 2020, the Board of Directors of the Company approved an option repricing which resulted in, for purposes of Section 16 of the Exchange Act, the cancellation of this option granted to her on December 10, 2019, in exchange for a new option having a lower exercise price of $2.45 per share, which is the closing price of the Company's common stock on April 22, 2020. All of the other terms of the option remained unchanged. F1 · derivative.exercise_date: Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years. Read SEC document |
| April 22, 2020 Filed Apr 24, 2020 21:30 UTC | Equillium, Inc. EQ · Entity 6560 | Disposition to issuerStock Option (right to buy) · Derivative | 90,000 | Not disclosed Strike: $4.75 | Not disclosed |
DisclosureSEC source: 0001209191-20-025655 · doc4.xml · derivative · entry 5 Zedelmayer Christine · CIK 0001797818 · Sr. Vice President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 90,000 shares Expires 2029-12-09 F4 · price: Effective April 22, 2020, the Board of Directors of the Company approved an option repricing which resulted in, for purposes of Section 16 of the Exchange Act, the cancellation of this option granted to her on December 10, 2019, in exchange for a new option having a lower exercise price of $2.45 per share, which is the closing price of the Company's common stock on April 22, 2020. All of the other terms of the option remained unchanged. F1 · derivative.exercise_date: Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years. Read SEC document |
| April 22, 2020 Filed Apr 24, 2020 21:30 UTC | Equillium, Inc. EQ · Entity 6560 | GrantStock Option (right to buy) · Derivative | 50,000 | Not disclosed Strike: $2.45 | Not disclosed |
DisclosureSEC source: 0001209191-20-025655 · doc4.xml · derivative · entry 4 Zedelmayer Christine · CIK 0001797818 · Sr. Vice President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2029-02-12 F3 · price: Effective April 22, 2020, the Board of Directors of the Company approved an option repricing which resulted in, for purposes of Section 16 of the Exchange Act, the cancellation of this option granted to her on February 13, 2019, in exchange for a new option having a lower exercise price of $2.45 per share, which is the closing price of the Company's common stock on April 22, 2020. All of the other terms of the option remained unchanged. F1 · derivative.exercise_date: Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years. Read SEC document |
| April 22, 2020 Filed Apr 24, 2020 21:30 UTC | Equillium, Inc. EQ · Entity 6560 | Disposition to issuerStock Option (right to buy) · Derivative | 50,000 | Not disclosed Strike: $7.16 | Not disclosed |
DisclosureSEC source: 0001209191-20-025655 · doc4.xml · derivative · entry 3 Zedelmayer Christine · CIK 0001797818 · Sr. Vice President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2029-02-12 F3 · price: Effective April 22, 2020, the Board of Directors of the Company approved an option repricing which resulted in, for purposes of Section 16 of the Exchange Act, the cancellation of this option granted to her on February 13, 2019, in exchange for a new option having a lower exercise price of $2.45 per share, which is the closing price of the Company's common stock on April 22, 2020. All of the other terms of the option remained unchanged. F1 · derivative.exercise_date: Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years. Read SEC document |
| April 22, 2020 Filed Apr 24, 2020 21:30 UTC | Equillium, Inc. EQ · Entity 6560 | GrantStock Option (right to buy) · Derivative | 35,695 | Not disclosed Strike: $2.45 | Not disclosed |
DisclosureSEC source: 0001209191-20-025655 · doc4.xml · derivative · entry 2 Zedelmayer Christine · CIK 0001797818 · Sr. Vice President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,695 Underlying: Common Stock · 35,695 shares Expires 2028-09-12 F2 · price: Effective April 22, 2020, the Board of Directors of the Company approved an option repricing which resulted in, for purposes of Section 16 of the Exchange Act, the cancellation of this option granted to her on September 13, 2018, in exchange for a new option having a lower exercise price of $2.45 per share, which is the closing price of the Company's common stock on April 22, 2020. All of the other terms of the option remained unchanged. F1 · derivative.exercise_date: Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years. Read SEC document |
| April 22, 2020 Filed Apr 24, 2020 21:30 UTC | Equillium, Inc. EQ · Entity 6560 | Disposition to issuerStock Option (right to buy) · Derivative | 35,695 | Not disclosed Strike: $3.87 | Not disclosed |
DisclosureSEC source: 0001209191-20-025655 · doc4.xml · derivative · entry 1 Zedelmayer Christine · CIK 0001797818 · Sr. Vice President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,695 shares Expires 2028-09-12 F2 · price: Effective April 22, 2020, the Board of Directors of the Company approved an option repricing which resulted in, for purposes of Section 16 of the Exchange Act, the cancellation of this option granted to her on September 13, 2018, in exchange for a new option having a lower exercise price of $2.45 per share, which is the closing price of the Company's common stock on April 22, 2020. All of the other terms of the option remained unchanged. F1 · derivative.exercise_date: Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.